Although colorectal cancer (CRC) is a prevalent malignancy of the digestive system, the underlying mechanisms of CRC tumorigenesis are still elusive. Arrestin-related domain-containing protein-3 (ARRDC3) has been reported to promote lysosome-mediated protein degradation. In the present study, we find that the expression of ARRDC3 is downregulated in CRC specimens. Mechanistically, we reveal that ARRDC3 binds and decreases expression of the oncoprotein YAP, the cotranscription factor of the Hippo pathway. The regulation of the Hippo pathway by ARRDC3 is conserved from Drosophila to mammals. Furthermore, we demonstrate that ARRDC3 plays an anti-oncogenic role in CRC progression by promoting YAP degradation. Finally, we show that ARRDC3 increases the sensitivity of CRC cells toward chemotherapeutic drugs. Taken together, our findings point to ARRDC3 as a potential target for CRC treatment.
Colorectal cancer (CRC) is the most common malignant tumor of the digestive system and the fourth most deadly cancer worldwide [1] . Although significant progress has been made in improving the therapy of CRC, the mortality rate still remains high because of cancer recurrence and metastasis [2] . In addition, the prognosis of CRC is also one of the longstanding difficulties because the CRC patient lacks obvious symptoms at the early stages [3] . Therefore, a deeper insight into the underlying mechanisms of CRC progression is urgently required to improve the prognosis and therapy of CRC.
Many signaling pathways are involved in CRC tumorigenesis. Hyperactivation of the Wnt pathway is a common cause of CRC [4, 5] . Several mutations are reported on b-catenin, an important component of the Wnt pathway [6, 7] . Furthermore, mounting evidence shows that the Hippo pathway also contributes to CRC tumorigenesis [8] . Numerous mutations on Hippo pathway components have been reported in CRC samples [9, 10] . The Hippo pathway was initially discovered in Drosophila with respect to its critical roles in restricting cell proliferation and promoting cell apoptosis [11] [12] [13] . The previous data have clearly demonstrated that Hippo pathway is a kinase cascade, whereby the MST1/2 and the adaptor SAV1 phosphorylate and activate the downstream kinase LATS1/2 [14, 15] . In turn, the LATS1/2 forms a complex with MOB1A/B to phosphorylate the cotranscription factor YAP, resulting in YAP cytoplasmic retention and inactivation [14] . Otherwise, when the Hippo pathway is off, YAP enters into the nucleus to trigger the expression of pro-proliferative and anti-apoptotic genes [16] . Therefore, YAP has been shown to be critical for cancer initiation and growth [15] . Although it is well known that the activity of YAP is controlled by its cellular localization, it is still unclear how YAP protein abundance is regulated.
Arrestin-related domain-containing protein-3 (ARRDC3) is a tumor suppressor in breast cancer [17] . The Nterminal region of ARRDC3 is homologous to the arrestin family, which plays an important role in the internalization and subsequent destabilization of many G-protein-coupled receptors [18] . A previous study demonstrated that ARRDC3 is downregulated in breast cancer samples. ARRDC3 plays the anti-tumor role, at least partly by promoting b-4 integrin degradation [17] . Another study reported that ARRDC3 degrades b2-adrenergic receptor (b2AR) by recruiting NEDD4 E3 ligase to b2AR [19] . The role of ARRDC3 in breast cancers is clear although it is still unknown whether ARRDC3 is involved in regulating CRC tumorigenesis.
In the present study, we found that the expression of ARRDC3 was decreased in CRC samples, and ARRDC3 levels were inversely correlated with the expression of YAP target genes. In CRC cell lines, knockdown of ARRDC3 increased the expression of YAP target genes, whereas overexpression of ARRDC3 played an opposing role. Using biochemical assays, we found that ARRDC3 bound YAP, resulting in YAP degradation. In addition, knockdown of ARRDC3 promoted the proliferation and metastasis of CRC cells via YAP, whereas ARRDC3 overexpression exerted opposing effects. We also found that the regulation of ARRDC3 upon Hippo signaling was conserved from Drosophila to mammals. Finally, we demonstrated that ARRDC3 increased the sensitivity of CRC cells to chemotherapy. In summary, our findings show that ARRDC3 suppresses CRC tumorigenesis through destabilizing YAP, thus pointing to ARRDC3 as a putative diagnostic biomarker and therapeutic target in CRC.
Materials and methods

Patient samples
Fresh-frozen primary CRC tissues and their paired normal samples were obtained from patients who were undergoing surgical resection at Qianfo Mount Hospital affiliated to Shandong University (Jinan, China) after obtaining consent from the patients. None of the patients had received any prior radiochemotherapy.
Constructs
To generate Fg-ARRDC3 and Myc-YAP plasmids, we amplified the corresponding cDNA fragments using DNA polymerase (P505; Vazyme, Nanjing, China) and then cloned them into CMV-Fg or pcDNA3.1-Myc vectors, respectively. UAS-HA-Leash and UAS-Myc-Yki were generated in accordance with methods described previously [20] . The primers used for construct generation were as follows: Fg-ARRDC3, 5
0 -CGGAATTCAATGGTGCTGG- Cell culture, transfection, and western blotting HEK-293T, HT-29, and HCT116 cells were gifts from S. Yuan (China Pharmaceutical University, Nanjing, China) and were cultured in Eagle's minimum essential medium (Gibco, Gaithersburg, MD, USA) containing 10% fetal bovine serum and 1% penicillin/streptomycin. S2 cells (a gift from the laboratory of E. Ling, Institute for Biological Sciences, Shanghai, China) were maintained in Schneider's Drosophila medium (Gibco) with 10% heatinactivated fetal bovine serum (Gibco) and 1% penicillin/ streptomycin (Sangon Biotech, Shanghai, China). Cells were transfected using polyethylenimine (Sigma, St Louis, MO, USA) in accordance with the manufacturer's instructions. Forty-eight hours after transfection, cells were harvested for immunoprecipitation and western blot analysis with standard protocols in accordance with methods described previously [21] . The antibodies used for the western blot analysis were as follows: mouse antiFg (M2; dilution 1 : 5000; Sigma); mouse anti-Myc (dilution 1 : 2000; Santa Cruz Biotechnology, Santa Cruz, CA, USA); mouse anti-actin (dilution 1 : 5000; GenScript Corporation, Piscataway, NJ, USA); mouse anti-YAP (dilution 1 : 1000; Santa Cruz Biotechnology); rabbit anti-N-cadherin (dilution 1 : 1000; Abclonal, Woburn, MA, USA); rabbit anti-CDH2 (dilution 1 : 1000; ABclonal); rabbit anti-Fak (dilution 1 : 1000; ABclonal); rabbit antivimentin (dilution 1 : 1000; ABclonal); rabbit anti-b-catenin (dilution 1 : 1000; ABclonal); rabbit anti-ARRDC3 (dilution 1 : 5000; ABclonal); goat anti-mouse horseradish peroxidase (dilution 1 : 10000; Abmax, Beijing, China); and goat anti-rabbit horseradish peroxidase (dilution 1 : 10000; Abmax). After western blots, the band intensity was measured using IMAGEJ (NIH, Bethesda, MD, USA) in accordance with a method described previously [22] .
Drosophila genetics
All stocks were obtained from Bloomington Drosophila Stock Center (Bloomington, IN, USA) and raised under standard conditions. Immunostaining of discs was performed using protocols described previously [20] . In brief, third-instar larvae were dissected in PBS and fixed in freshly made 4% formaldehyde in PBS at room temperature for 20 min and then washed three times with PBT (PBS plus 0.1% Triton X-100). Larvae were incubated overnight with the required primary antibodies in PBT at 4°C, then washed with PBT for three times and incubated with corresponding fluorophore-conjugated secondary antibody for 2 h at room temperature. After being washed for three times in PBT, discs were dissected and mounted in 40% glycerol. Images were captured using a confocal microscope (Carl Zeiss, Oberkochen, Germany). The antibodies used were as follows: rabbit anti-Yki (dilution 1 : 1000; a gift from S. Wu, Nankai University, Tianjin, China); rabbit anti-DIAP1 (dilution 1 : 100; a gift from S. Hayashi, RIKEN Brain Science Institute, Wako, Japan); and Cy3-conjugated goat anti-rabbit antibody (dilution 1 : 500; Jackson ImmunoResearch, West Grove, PA, USA).
RNA interference
To silence ARRDC3 or YAP in HCT116 or HT-29 cells, small interfering RNAs (siRNAs) were transfected at a final concentration of 100 nM using Lipo2000 (Invitrogen, Carlsbad, CA, USA) in accordance with a previous study [20] . For ARRDC3 knockdown, a mixture of two distinct siRNAs was used. The siRNA sequences were as follows:
Immunofluorescence HT-29 cells cultured on coverslips were fixed with freshly made 4% formaldehyde in PBS at room temperature for 20 min and were then permeabilized by incubating with PBT (PBS plus 0.1% Triton X-100). Slides were incubated overnight with primary antibodies (rabbit anti-ARRDC3
and mouse anti-YAP) at 4°C, then washed with PBS for three times and incubated with corresponding fluorophoreconjugated secondary antibody for 2 h at room temperature. 4 0 ,6-Diamidino-2-phenylindole (DAPI) was used to mark the nucleus. Images were captured with a confocal microscope (Carl Zeiss).
MTT assay
3-(4,5-Dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were carried out as described previously [23] . In brief, after different treatments, log-phase cells were seeded into 96-well plates (5 9 10 3 cells per well). At 48 h after transfection, 20 lL of MTT (5 mgÁmL À1 ) was added, followed by additional incubation at 37°C for 4 h before discarding the supernatants. Then, 100 lL of dimethylsulfoxide was added to each well before shaking gently for 10 min to dissolve crystals. The absorbance of each well was measured at 490 nm using microplate reader. The viability of tumor cells = absorbance of treatment wells/absorbance of control well 9 100%. Data are reported as the mean AE SD of the values obtained from at least three experiments. 
Transwell assay
A transwell assay was carried out as described previously [23] . In brief, after indicated treatments, equivalent cells were seeded on top of a thick layer of Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) in transwell inserts (Corning Inc., New York, NY, USA) and cultured for another 24 h. Invasive cells adhered to the lower surface of filter were washed with PBS, fixed with 4% paraformaldehyde and stained with 0.05% crystal violet (Sangon Biotech). The invasive cells were counted under a light microscope.
RNA isolation, reverse transcription, and realtime PCR
Cells or HCC samples were lysed in Trizol (Invitrogen) for RNA isolation in accordance with protocols described previously [20] . 
Statistical analysis
Statistical analysis was carried out using PRISM (GraphPad Software Inc., San Diego, CA, USA). The reported data are representative of at least three independent experiments and were analyzed by one-way analysis of variance. P < 0.05 was considered statistically significant. Where exact P values are not shown, statistical significance was as follows: P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***).
Results
ARRDC3 is downregulated in CRC samples
Although it is clear that ARRDC3 acts as a tumor suppressor in several types of cancer, including breast cancer and prostate cancer [17, 24, 25] , its role in CRCs still remains unexplored. To investigate the potential role of ARRDC3 in the tumorigenesis of CRC, we first assessed its expression level by western blotting in 26 pairs of matched tissue samples. We measured the protein bands using IMAGEJ and normalized to actin. Compared with the corresponding normal counterparts, protein levels of ARRDC3 were decreased in 22 of 26 CRC tumors (Fig. 1A,B) . Consistently, Kaplan-Meier plotter analysis from the Oncomine database (https://www.oncomine. org) also revealed that ARRDC3 mRNA was downregulated in CRC samples (Fig. 1C) . Taken together, our findings demonstrate that CRC samples show decreased ARRDC3 expression, suggesting that ARRDC3 is possibly involved in CRC tumorigenesis. 
ARRDC3 decreases the expression of YAP target genes
Because the above data showed that ARRDC3 was downregulated in CRC samples, it was logical to explore the role of ARRDC3 in CRC tumorigenesis. Intriguingly, mass spectrometric analyses showed that Leash (ARRDC3 ortholog in Drosophila) interacted with Yki (YAP ortholog in Drosophila) [26] , inferring that ARRDC3 likely regulates Hippo signaling. We chose two pairs of matched tissue samples (case 8 and case 11) with an apparent ARRDC3 decrease to carry out real-time PCR assays. The results showed that the transcription of YAP target genes was apparently increased in CRC samples ( Fig. 2A , In all results, *P < 0.05, **P < 0.01 and ***P < 0.001 by analysis of variance. ns, no significance. B). We further found that these CRC samples showed increased YAP protein, whereas the YAP mRNA level had no detectable changes ( Fig. 2A  0 ,B  0 ). In addition, we employed CRC cell lines to validate this result. Knockdown of ARRDC3 promoted YAP target gene expression in HT-29 cells (Fig. 2C) , whereas overexpression of ARRDC3 exerted an opposing effect (Fig. 2D) . Consistently, overexpression of ARRDC3 decreased the mRNA levels of YAP target genes, without any obvious effect on YAP mRNA in HCT-116 cells (Fig. 2E) . Collectively, ARRDC3 is a negative regulator for Yap target gene expression.
ARRDC3 binds YAP to promote YAP degradation
ARRDC3 is a member of the mammalian a-arrestins family and plays an important role in promoting lysosome-mediated destabilization of many targets [17, 18] . Consistent with the latest finding [27] , we found that YAP protein was unstable (Fig. 3A) and was degraded by lysosome (Fig. 3B ). In addition, knockdown of ARRDC3 blocked the degradation of YAP (Fig. 3C) , indicating that ARRDC3 possibly regulates YAP destabilization. To address this possibility, we first examined the interaction between YAP and ARRDC3. The co-immunoprecipitation assays showed that YAP reciprocally bound ARRDC3 in HEK-293T cells (Fig. 3D,E) . We confirmed this result in HCT116 cells (Fig. 3F) . Furthermore, the endogenous YAP could pull down endogenous ARRDC3 in HCT116 cells and HT-29 cells (Fig. 3G,H) . On the other hand, via immunofluorescence analyses, we found that YAP co-localized with ARRDC3 in the cytoplasm (Fig. 3I) .
Given that ARRDC3 binds YAP and knockdown of ARRDC3 accelerates YAP degradation, it is necessary to test whether ARRDC3 promotes lysosome-mediated YAP destabilization. We found that overexpression of ARRDC3 indeed decreased YAP protein in 293T cells (Fig. 3J ) and CRC cell lines (Fig. 3K,L) and that this decrease was effectively overcome by lysosome inhibitor NH 4 Cl treatment (Fig. 3K,L) . Furthermore, the semiquantitative PCR assay showed that neither ARRDC3 knockdown nor ARRDC3 overexpression affected the transcription of YAP (Fig. 3M) , removing the possibility that ARRDC3 regulates YAP at mRNA level. In sum, ARRDC3 binds YAP to promote lysosome-mediated YAP degradation.
The regulation of the Hippo pathway by ARRDC3 is conserved
Because the above data showed that ARRDC3 modulates Hippo pathway via promoting YAP degradation in mammalian cells, we wanted to test whether this mechanism is conserved in Drosophila. Consistently, Leash (ARRDC3 ortholog) also interacted with Yki (YAP ortholog) in S2 cells (Fig. 4A) . Furthermore, the cell staining assay revealed that Leash and Yki co-localized in the cytoplasm (Fig. 4B-B  000 ), indicating the possibility of the Hippo-Yki pathway being regulated by Leash in Drosophila. To address this possibility, we overexpressed or silenced Leash in the wing disc using En-gal4. Overexpression of Leash substantially decreased DIAP1, which is a well-known Yki target gene (Fig. 4C-C  00 ). By contrast, knockdown of Leash elevated DIAP1 (Fig. 4D-D 00 ). Additionally, overexpression of Leash mildly decreased the Yki protein level in the wing disc (Fig. 4E-E  00 ). Taken together, the in vivo results demonstrate that Leash plays a similar role as ARRDC3 in regulating Hippo pathway in Drosophila.
ARRDC3 decreases the proliferation and metastasis of CRC cells
Because our above data showed an inverse correlation between ARRDC3 and CRC, we next wanted to For all of the above, data are the mean AE SD from at least three independent experiments. For all results, *P < 0.05, **P < 0.01, and ***P < 0.001 (analysis of variance).
examine whether ARRDC3 regulates the oncogenic properties of CRC cells. Consistently, knockdown of ARRDC3 promoted HT-29 cell proliferation (Fig. 5A) , whereas overexpression of ARRDC3 attenuated cell proliferation (Fig. 5A) . The epithelial-mesenchymal transition is a critical event during tumorigenesis and migration by which the epithelial cells acquire mesenchymal properties and show decreased intercellular adhesion and increased motility [28] . Indeed, we found that overexpression of ARRDC3 decreased mesenchymal markers, including N-cadherin, CDH2, Fak, vimentin, and b-catenin, in both HCT116 and HT-29 cells (Fig. 5B) , whereas knockdown of ARRDC3 upregulated mesenchymal markers (Fig. 5C) . We also tested the cell migration via transwell assay and found that ARRDC3 knockdown promoted, whereas ARRDC3 overexpression inhibited, cell migration (Fig. 5F ). Taken together, these results indicate that ARRDC3 plays an anti-tumor role in CRC.
The finding that ARRDC3 promoting YAP destabilization prompted us to explore whether ARRDC3 regulates CRC tumorigenesis via YAP. The increased cell proliferation induced by ARRDC3 knockdown was overcome by YAP silencing (Fig. 5D,E) . Furthermore, the attenuated cell proliferation caused by ARRDC3 overexpression was also restored by YAP transfection (Fig. 5D,E) , suggesting that ARRDC3 suppresses CRC cell proliferation through destabilizing oncoprotein YAP. In addition, ARRDC3 regulated cell migration also via YAP (Fig. 5F ). Taken together, these results suggest that ARRDC3 plays an antitumor role via the Hippo-Yap axis. The resistance of cancer cells to chemotherapies is a major cause of disease recurrence and the poor survival of CRC patients [29] . To explore whether ARRDC3 affects the sensitivity of CRC cells to chemotherapies, HCT116 or HT-29 cells with different transfections (ARRDC3-siRNA or Fg-ARRDC3) were treated with various chemotherapeutical drugs including Adriamycin, cisplatin, and 5-fluorouracil, at concentrations described previously [29] . Cell proliferation in the presence of the drugs was consistently higher in ARRDC3-siRNA cells compared to that in MOCK-siRNA cells (Fig. 6A,C) , indicating that knockdown of ARRDC3 decreases the sensitivity of CRC cells toward chemotherapeutical drugs. Consistently, overexpression of ARRDC3 elevated the sensitivity of CRC cells to drugs (Fig. 6B,D) . Taken together, these results suggest that a low expression of ARRDC3 possibly contributes to the enhanced resistance toward chemotherapies CRC patients.
Discussion
In the present study, we found that ARRDC3 was decreased in CRC samples and inversely correlated with CRC cell proliferation and migration. We provided both loss-of-function and gain-of-function evidence showing that ARRDC3 suppresses CRC tumorigenesis through destabilizing the oncoprotein YAP. Mechanistically, ARRDC3 interacted with YAP in different cells, indicating that ARRDC3 is a bonafide modulator of Hippo-YAP signaling. In addition, we revealed that ARRDC3 increased the sensitivity of CRC cells toward distinct chemotherapeutic drugs.
The mammalian genome encodes at least four ARRDC proteins, including ARRDC1, ARRDC2, ARRDC3, and ARRDC4 [30] . It will be interesting to test whether these four ARRDC proteins play redundant roles in CRC tumorigenesis. In both mice and humans, ARRDC3 is ubiquitously expressed and its expression is controlled by feeding/fasting in several metabolically relevant tissues [30] . It is well known that Hippo-Yap signaling could respond to external metabolic hints [31] . Therefore, it is of interest to explore whether the metabolic stimuli regulate Hippo pathway outputs by modulating ARRDC3 expression. In the present study, it is still unclear how ARRDC3 promotes YAP degradation. Indeed, previous studies have revealed that ARRDC3 only acts as a scaffold that recruits NEDD4 E3 ligase to the substrate, including b2AR [19] . In the future, we will aim to determine whether ARRDC3 destabilizes YAP via a similar mechanism.
The prognosis of CRC is still a challenge as a result of the lack of symptoms in early CRC patients. Thus, there is an urgent need to identify a biomarker for CRC clinic prognosis. In the present study, we found that ARRDC3 is downregulated in CRC samples, indicating that ARRDC3 is a potential marker for the early diagnosis of CRC. Overexpression of ARRDC3 neutralized the resistance of CRC cells toward chemotherapeutic drugs, suggesting that ARRDC3 acts as a putative target for CRC treatment. In the future, we may combine chemotherapeutic drugs and ARRDC3 agonists to effectively intervene against CRC.
